Should the Rich Be Allowed to Buy the Best Genes?
By Walter Isaacson,
Air Mail
| 07. 27. 2019
QUEBEC CITY
Biology is the new tech. I’m at a conference in Quebec City on CRISPR, the molecular tool designed to edit genes, and it has the same vibe as the meetings of the Homebrew Computer Club and the West Coast Computer Faire did in the 1970s, except that the hip young innovators are programming with genetic code rather than computer code. Now that schools are finally realizing that every kid should learn how to code, they are going to have to switch from teaching 0101 to A.G.C.T., the four bases of our DNA.
Many of the star pioneers are here, including Berkeley’s Jennifer Doudna, who in 2012 co-discovered how to combine two snippets of RNA with an enzyme to make a programmable scissors that could cut DNA at a precise location, and Feng Zhang of the Broad Institute, who raced her to show how the tool could edit genes in humans and is now in a battle with her for patents to the technology.
The atmosphere is charged with the catalytic combination of competition and cooperation reminiscent of when...
Related Articles
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...
By Noah Fromson, HealthLab | 10.19.2026
Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care.
There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets...
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...